Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDE225 in High-risk Localized Prostate Cancer
NCT02111187Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2014
- Primary completion
- Jan 2017
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in prostate cancer (PCa) comparing LDE225 with Observation (2 arms). Primary endpoint: Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis at 4 weeks. Started Apr 2014; status: completed.
02
Drugs
sonidegib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02111187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02111187.